Encapsulation of S-nitrosoglutathione: a transcriptomic validation
Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO * ) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO * , the encapsulation of GSNO into nanoparticles may be an interesting option....
Gespeichert in:
| Veröffentlicht in: | Drug development and industrial pharmacy 2019-03, Vol.45 (3), p.423-429 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 3 |
| container_start_page | 423 |
| container_title | Drug development and industrial pharmacy |
| container_volume | 45 |
| creator | Safar, Ramia Houlgatte, Rémi Le Faou, Alain Ronzani, Carole Wu, Wen Ferrari, Luc Dubois-Pot-Schneider, Hélène Rihn, Bertrand H. Joubert, Olivier |
| description | Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO
*
) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO
*
, the encapsulation of GSNO into nanoparticles may be an interesting option.
Methods: In this work, we have investigated the early (4 h) and late (24 h) transcriptomic response of THP-1 human monocytes cells to two doses (1.4 and 6 µM) of either free or Eudragit
®
nano-encapsulated GSNO using RNA microarray.
Results: After exposure to free GSNO, genes mainly involved in apoptosis, cell differentiation, immune response and metabolic processes were differentially expressed. Although, cells exposed to free or encapsulated GSNO behave differently, activation of genes involved in blood coagulation, immune response and cell cycle was observed in both conditions.
Conclusions: These results suggest that the encapsulation of low doses of GSNO into Eudragit
®
nanoparticles leads to a progressive release of GSNO making this compound a possible oral therapy for several biomedical applications like inflammatory bowel diseases. |
| doi_str_mv | 10.1080/03639045.2018.1546313 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_30449192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2135641040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-a28e4d91331e4899a4912ee5e0ce163c3905519ab98bc30a8940de5c8694ca8e3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EokvhJ4ByhEOWmdgONidKVSjSShyAszXrONTIiRfbKeq_x2G3PXIaafS88_Ew9hJhi6DgLfCeaxBy2wGqLUrRc-SP2AZlB61813eP2WZl2hU6Y89y_gWAnZbyKTvjIIRG3W3Yx6vZ0iEvgYqPcxPH5ls7-5Jijj_DUqjc1LZ731BTEs3ZJn8ocfK2uaXgh3-h5-zJSCG7F6d6zn58uvp-ed3uvn7-cnmxa60AKC11yolBI-fohNKa6gWdc9KBddhzW7-REjXttdpbDqS0gMFJq3otLCnHz9mb49wbCuaQ_ETpzkTy5vpiZ9YeoJadUniLlX19ZA8p_l5cLmby2boQaHZxyaZDLnuBIKCi8oja-nRObnyYjWBW1eZetVlVm5Pqmnt1WrHsJzc8pO7dVuDDEfDzGNNEf2IKgyl0F2Iaq0zrs-H_3_EXWpaMIg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2135641040</pqid></control><display><type>article</type><title>Encapsulation of S-nitrosoglutathione: a transcriptomic validation</title><source>Business Source Complete</source><creator>Safar, Ramia ; Houlgatte, Rémi ; Le Faou, Alain ; Ronzani, Carole ; Wu, Wen ; Ferrari, Luc ; Dubois-Pot-Schneider, Hélène ; Rihn, Bertrand H. ; Joubert, Olivier</creator><creatorcontrib>Safar, Ramia ; Houlgatte, Rémi ; Le Faou, Alain ; Ronzani, Carole ; Wu, Wen ; Ferrari, Luc ; Dubois-Pot-Schneider, Hélène ; Rihn, Bertrand H. ; Joubert, Olivier</creatorcontrib><description>Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO
*
) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO
*
, the encapsulation of GSNO into nanoparticles may be an interesting option.
Methods: In this work, we have investigated the early (4 h) and late (24 h) transcriptomic response of THP-1 human monocytes cells to two doses (1.4 and 6 µM) of either free or Eudragit
®
nano-encapsulated GSNO using RNA microarray.
Results: After exposure to free GSNO, genes mainly involved in apoptosis, cell differentiation, immune response and metabolic processes were differentially expressed. Although, cells exposed to free or encapsulated GSNO behave differently, activation of genes involved in blood coagulation, immune response and cell cycle was observed in both conditions.
Conclusions: These results suggest that the encapsulation of low doses of GSNO into Eudragit
®
nanoparticles leads to a progressive release of GSNO making this compound a possible oral therapy for several biomedical applications like inflammatory bowel diseases.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1080/03639045.2018.1546313</identifier><identifier>PMID: 30449192</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Biochemistry, Molecular Biology ; Cellular Biology ; Genomics ; Life Sciences ; monocytes ; nitric oxide ; polymeric nanoparticles ; S-nitrosoglutathione ; Toxicology ; transcriptome</subject><ispartof>Drug development and industrial pharmacy, 2019-03, Vol.45 (3), p.423-429</ispartof><rights>2018 Informa UK Limited, trading as Taylor & Francis Group 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-a28e4d91331e4899a4912ee5e0ce163c3905519ab98bc30a8940de5c8694ca8e3</citedby><cites>FETCH-LOGICAL-c400t-a28e4d91331e4899a4912ee5e0ce163c3905519ab98bc30a8940de5c8694ca8e3</cites><orcidid>0000-0002-3545-1675 ; 0000-0002-5799-7951 ; 0000-0002-3159-6826 ; 0000-0003-3374-1481</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30449192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-01952881$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Safar, Ramia</creatorcontrib><creatorcontrib>Houlgatte, Rémi</creatorcontrib><creatorcontrib>Le Faou, Alain</creatorcontrib><creatorcontrib>Ronzani, Carole</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Ferrari, Luc</creatorcontrib><creatorcontrib>Dubois-Pot-Schneider, Hélène</creatorcontrib><creatorcontrib>Rihn, Bertrand H.</creatorcontrib><creatorcontrib>Joubert, Olivier</creatorcontrib><title>Encapsulation of S-nitrosoglutathione: a transcriptomic validation</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO
*
) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO
*
, the encapsulation of GSNO into nanoparticles may be an interesting option.
Methods: In this work, we have investigated the early (4 h) and late (24 h) transcriptomic response of THP-1 human monocytes cells to two doses (1.4 and 6 µM) of either free or Eudragit
®
nano-encapsulated GSNO using RNA microarray.
Results: After exposure to free GSNO, genes mainly involved in apoptosis, cell differentiation, immune response and metabolic processes were differentially expressed. Although, cells exposed to free or encapsulated GSNO behave differently, activation of genes involved in blood coagulation, immune response and cell cycle was observed in both conditions.
Conclusions: These results suggest that the encapsulation of low doses of GSNO into Eudragit
®
nanoparticles leads to a progressive release of GSNO making this compound a possible oral therapy for several biomedical applications like inflammatory bowel diseases.</description><subject>Biochemistry, Molecular Biology</subject><subject>Cellular Biology</subject><subject>Genomics</subject><subject>Life Sciences</subject><subject>monocytes</subject><subject>nitric oxide</subject><subject>polymeric nanoparticles</subject><subject>S-nitrosoglutathione</subject><subject>Toxicology</subject><subject>transcriptome</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi0EokvhJ4ByhEOWmdgONidKVSjSShyAszXrONTIiRfbKeq_x2G3PXIaafS88_Ew9hJhi6DgLfCeaxBy2wGqLUrRc-SP2AZlB61813eP2WZl2hU6Y89y_gWAnZbyKTvjIIRG3W3Yx6vZ0iEvgYqPcxPH5ls7-5Jijj_DUqjc1LZ731BTEs3ZJn8ocfK2uaXgh3-h5-zJSCG7F6d6zn58uvp-ed3uvn7-cnmxa60AKC11yolBI-fohNKa6gWdc9KBddhzW7-REjXttdpbDqS0gMFJq3otLCnHz9mb49wbCuaQ_ETpzkTy5vpiZ9YeoJadUniLlX19ZA8p_l5cLmby2boQaHZxyaZDLnuBIKCi8oja-nRObnyYjWBW1eZetVlVm5Pqmnt1WrHsJzc8pO7dVuDDEfDzGNNEf2IKgyl0F2Iaq0zrs-H_3_EXWpaMIg</recordid><startdate>20190304</startdate><enddate>20190304</enddate><creator>Safar, Ramia</creator><creator>Houlgatte, Rémi</creator><creator>Le Faou, Alain</creator><creator>Ronzani, Carole</creator><creator>Wu, Wen</creator><creator>Ferrari, Luc</creator><creator>Dubois-Pot-Schneider, Hélène</creator><creator>Rihn, Bertrand H.</creator><creator>Joubert, Olivier</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3545-1675</orcidid><orcidid>https://orcid.org/0000-0002-5799-7951</orcidid><orcidid>https://orcid.org/0000-0002-3159-6826</orcidid><orcidid>https://orcid.org/0000-0003-3374-1481</orcidid></search><sort><creationdate>20190304</creationdate><title>Encapsulation of S-nitrosoglutathione: a transcriptomic validation</title><author>Safar, Ramia ; Houlgatte, Rémi ; Le Faou, Alain ; Ronzani, Carole ; Wu, Wen ; Ferrari, Luc ; Dubois-Pot-Schneider, Hélène ; Rihn, Bertrand H. ; Joubert, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-a28e4d91331e4899a4912ee5e0ce163c3905519ab98bc30a8940de5c8694ca8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biochemistry, Molecular Biology</topic><topic>Cellular Biology</topic><topic>Genomics</topic><topic>Life Sciences</topic><topic>monocytes</topic><topic>nitric oxide</topic><topic>polymeric nanoparticles</topic><topic>S-nitrosoglutathione</topic><topic>Toxicology</topic><topic>transcriptome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Safar, Ramia</creatorcontrib><creatorcontrib>Houlgatte, Rémi</creatorcontrib><creatorcontrib>Le Faou, Alain</creatorcontrib><creatorcontrib>Ronzani, Carole</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Ferrari, Luc</creatorcontrib><creatorcontrib>Dubois-Pot-Schneider, Hélène</creatorcontrib><creatorcontrib>Rihn, Bertrand H.</creatorcontrib><creatorcontrib>Joubert, Olivier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Safar, Ramia</au><au>Houlgatte, Rémi</au><au>Le Faou, Alain</au><au>Ronzani, Carole</au><au>Wu, Wen</au><au>Ferrari, Luc</au><au>Dubois-Pot-Schneider, Hélène</au><au>Rihn, Bertrand H.</au><au>Joubert, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Encapsulation of S-nitrosoglutathione: a transcriptomic validation</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2019-03-04</date><risdate>2019</risdate><volume>45</volume><issue>3</issue><spage>423</spage><epage>429</epage><pages>423-429</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Objective: S-nitrosogluthatione (GSNO), a S-nitrosothiol, is a commonly used as nitric oxide (NO
*
) donor. However, its half-life is too short for a direct therapeutic use. To protect and ensure a sustained release of NO
*
, the encapsulation of GSNO into nanoparticles may be an interesting option.
Methods: In this work, we have investigated the early (4 h) and late (24 h) transcriptomic response of THP-1 human monocytes cells to two doses (1.4 and 6 µM) of either free or Eudragit
®
nano-encapsulated GSNO using RNA microarray.
Results: After exposure to free GSNO, genes mainly involved in apoptosis, cell differentiation, immune response and metabolic processes were differentially expressed. Although, cells exposed to free or encapsulated GSNO behave differently, activation of genes involved in blood coagulation, immune response and cell cycle was observed in both conditions.
Conclusions: These results suggest that the encapsulation of low doses of GSNO into Eudragit
®
nanoparticles leads to a progressive release of GSNO making this compound a possible oral therapy for several biomedical applications like inflammatory bowel diseases.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>30449192</pmid><doi>10.1080/03639045.2018.1546313</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3545-1675</orcidid><orcidid>https://orcid.org/0000-0002-5799-7951</orcidid><orcidid>https://orcid.org/0000-0002-3159-6826</orcidid><orcidid>https://orcid.org/0000-0003-3374-1481</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9045 |
| ispartof | Drug development and industrial pharmacy, 2019-03, Vol.45 (3), p.423-429 |
| issn | 0363-9045 1520-5762 |
| language | eng |
| recordid | cdi_pubmed_primary_30449192 |
| source | Business Source Complete |
| subjects | Biochemistry, Molecular Biology Cellular Biology Genomics Life Sciences monocytes nitric oxide polymeric nanoparticles S-nitrosoglutathione Toxicology transcriptome |
| title | Encapsulation of S-nitrosoglutathione: a transcriptomic validation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A01%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Encapsulation%20of%20S-nitrosoglutathione:%20a%20transcriptomic%20validation&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Safar,%20Ramia&rft.date=2019-03-04&rft.volume=45&rft.issue=3&rft.spage=423&rft.epage=429&rft.pages=423-429&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1080/03639045.2018.1546313&rft_dat=%3Cproquest_pubme%3E2135641040%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2135641040&rft_id=info:pmid/30449192&rfr_iscdi=true |